Ajay Srivastava of Dimensions Capital says the pharma sector will give good returns from a 3-5 year perspective.
He believes the sector will give good returns from a 3-5 year perspective. On Sun Pharma, that is currently in the news due to the USFDA warning on its Halol facility, Srivastava has a target of Rs 550-600 per share.
Furthermore, he says the market is in the right place as there is complacency that 7500 will hold. However, he says the upcoming year will see midcap stocks outperforming indices yet again.
Stay tuned for more.